Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_2
2
29%
Ph phase_3
4
57%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
4(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 34 (57.1%)

Trials by Status

terminated229%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus

NCT00739635
completedphase_3

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

NCT00955799
terminatedphase_3

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

NCT00827008
completedphase_3

Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

NCT00772980
terminatedphase_2

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

NCT00799942
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00739635Phase 3

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus

Completed
NCT00955799Phase 3

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

Completed
NCT00827008Phase 3

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

Terminated
NCT00772980Phase 3

Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

Completed
NCT00799942Phase 2

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Terminated
NCT00712283Phase 1

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

Completed
NCT00661440Phase 2

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7